Difference between revisions of "Axitinib (Inlyta)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 27: Line 27:
 
[[Category:Drug index]]
 
[[Category:Drug index]]
 
[[Category:Chemotherapy]]
 
[[Category:Chemotherapy]]
[[Category:Oral chemotherapy]]
+
[[Category:Oral medications]]
  
 
[[Category:Kinase inhibitors]]
 
[[Category:Kinase inhibitors]]

Revision as of 16:57, 25 July 2017

General information

Class/mechanism: Tyrosine kinase inhibitor of vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression, at picomolar concentrations. Inhibits PDGFRA, PDGFRB and c-kit at nanomolar concentrations.[1][2][3][4]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1/27/2012: Initial FDA approval "for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy."

Also known as

AG013736, AG-013736.

References